Our R&D groups in Oncology focus on a balanced portfolio of innovative targets as well as more established approaches. These groups are organized around five Innovation Clusters:
- Oncogenic signaling
- Antibody-Drug Conjugates
- DNA Damage & Repair
- Tumor Metabolism
- Tumor Plasticity
We actively search and evaluate technologies, preclinical and clinical assets that are able to support and strengthen our Innovation Clusters, and have clear differentiation potential.
Our search space includes antibodies against tumor antigens suitable for antibody-drug conjugation or pro-drug approaches for antibody therapeutics, as well as differentiated bi-specific platform technologies and antibody/protein scaffolds. Selective small molecule assets with well-defined molecular targets that show anti-tumor activity in specific contexts are also a priority, such as those with a proven synthetic lethality relationship in the area of DNA damage and repair, or those controlling tumorigenic metabolic networks in particular cancer genotypes.
In addition to preclinical and clinical assets, we are also interested in biomarker and technology platforms for the advancement of cancer therapies.
Global Business Development (GBD) & External Innovation (EI) work closely together to broaden our access to the world of scientific innovation. Please contact the GBD team in case you are looking for a partner post clinical Proof of Concept. Please contact the EI team for proposal in the pre-clinical and early clinical space up to clinical Proof of Concept.